Previous 10 | Next 10 |
2024-02-01 07:22:58 ET Summary Vyvgart generated $1.2 billion in net sales in 2023 and is in a good position to continue performing well in 2024 and beyond. Empasiprubart has generated strong results in the first cohort of MMN patients, putting this candidate on investors' radars ...
Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncology PR Newswire Five p...
2024-01-04 14:57:40 ET More on SPDR S&P Biotech ETF: Biopharmaceutical Stocks: The Rally Has Just Begun Get Ready For The New Biotech Bull Market Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biotechs p...
Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire NEW HAVEN, Conn. , Jan. 2, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at ...
2023-12-20 08:36:29 ET Losers: Bluebird bio BLUE -52% on pricing of $125 million stock offering . Jin Medical International Ltd ( ZJYL ) -14% . Argen X SE ( ARGX ) -25% reports topline results from address study of Efgartigimod SC in Pemphigus . ...
2023-12-08 12:14:24 ET Summary Today, we circle back on a promising biopharma concern called Biohaven Ltd., whose shares have had a significant rally in recent months. The company has a diverse pipeline of therapies for neurological and neuropsychiatric diseases, with a mixture of...
Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting PR Newswire Biohaven reported full results from the BHV-7000 Phase 1 study examining doses up to 120 mg daily, demonstrating BHV-7000 was well-tolerated at all doses stu...
2023-11-25 02:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Shares of Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) traded at a new 52-week high today and are currently trading at $27.63. So far today, approximately 555.29k shares have been exchanged, as compared to an average 30-day volume of 1.31M shares. Biohaven Pharmaceutical Holding ...
2023-11-14 17:13:43 ET More on Biohaven Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True Biohaven's Valuation Challenge: Weighing Potential Against Setbacks Biohaven raises $258.7M from public offering Biohaven shares slide on pricing $2...
News, Short Squeeze, Breakout and More Instantly...
Biohaven Pharmaceutical Holding Company Ltd. Company Name:
BHVN Stock Symbol:
NYSE Market:
Biohaven Pharmaceutical Holding Company Ltd. Website:
2024-07-20 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-29 12:00:07 ET Brian Skorney from Robert W. Baird issued a price target of $58.00 for BHVN on 2024-05-29 09:57:00. The adjusted price target was set to $58.00. At the time of the announcement, BHVN was trading at $30.31. The overall price target consensus is at $...